Acute GVHD (aGVHD) is a serious complication after allogeneic SCT (allo-SCT). However, an adequate immunological index is not yet available for assessing its severity. We analyzed the fraction of cutaneous lymphocyte antigen (CLA) þ cells in peripheral blood T and natural killer (NK) cells in 33 patients and evaluated its association with aGVHD. The CLA þ T-cell fraction often increased 3-7 days before the onset of aGVHD, and the maximum percentage of CLA þ T cells in grades II-IV aGVHD cases was significantly higher than that in grade 0 or I aGVHD (Po0.01). When the cutoff value of the maximum CLA þ T-cell percentage was set at 20%, any higher percentage was a significant risk for the development of severe aGVHD (Po0.0001). The maximum CLA þ T-cell percentage was significantly correlated with a high body temperature, low percutaneous oxygen saturation, and fibrinogen/fibrin degradation product D-dimer level. The post-allo-SCT CLA þ T cells exhibited a high ability to produce IL-2 and IFN-c, and may be the effectors and immunological markers for aGVHD. The CLA þ NK-cell-fraction steadily increased 2-4 weeks after allo-SCT but was not influenced by aGVHD. The CLA
Introduction
Acute GVHD (aGVHD) is the putative immunological reaction of transplanted bone marrow or lymphoid cells against target organs such as the skin, gastrointestinal tract or liver.
1,2 Most cases begin with skin lesions that appear 2-3 weeks after allogeneic SCT (allo-SCT). In the afferent phase of aGVHD, the production of IFN-g and IL-2, referred to as type-1-helper-T (Th1)-cell cytokine response, is predominantly induced by alloantigens and proinflammatory cytokines such as IL-1, IL-12 and tumor necrosis factor (TNF)-a that are produced by macrophages or antigen-presenting cells following organ damage by conditioning chemoradiotherapy. [3] [4] [5] [6] [7] It has been postulated that T cells activated with allo-antigens in this cytokine environment migrate to target organs, and form the characteristic clinicopathological changes of aGVHD.
It has been revealed that homing receptors make the memory T cells return to specific secondary lymphoid tissues or extralymphoid tissues in which the T cells were first activated with antigens. 8, 9 Among them, the cutaneous lymphocyte antigen (CLA)-a sialylated P-selectin glycoprotein ligand-1-mediates the specific skin homing of T or natural killer (NK) cells circulating in the peripheral blood (PB). [10] [11] [12] [13] [14] The microenvironment of skin or skin-associated lymph node that is necessary for CLA expression has not been fully clarified. However, in in vitro experiments, the CLA expression on T cells was specifically induced by stimulation with IL-2, IL-12 and phytohemagglutinin (PHA, antigen signal), whereas that on NK cells was induced by stimulation with IL-2 and IL-12.
13,14 These experimental conditions are analogous to the cytokine environment in the afferent phase of aGVHD as mentioned above, and suggest the involvement of CLA in the pathogenesis of aGVHD. Recent work using human material has partially indicated the association of CLA with cutaneous aGVHD, 15 but the role of CLA in systemic aGVHD and aGVHD grade has not been sufficiently investigated in clinical settings.
In this study, we investigated the alterations in CLA þ T and NK cells after allo-SCT and evaluated the potential of CLA as an immunobiological marker for the assessment of aGVHD severity.
Materials and methods

Patients
From 2000 to 2005, 33 patients underwent allo-SCT at Niigata University Medical School (Table 1) . The treatment protocols were approved by the Niigata University Institutional Review Board. Informed consent was obtained from all patients participating in this study. Patients receiving corticosteroids continuously for either aGVHD prophylaxis or other purposes were excluded from this study, whereas those receiving corticosteroids after the onset of severe aGVHD were enrolled. Patients treated with nonmyeloablative or cord-blood transplantation were excluded. Stem cells of HLA-matched relatives or unrelated donors from the Japan Bone Marrow Transplantation Registry were used.
After allo-SCT, engraftment was defined as occurring on the first of the 3 consecutive days during which the donor ANC exceeded 0.5 Â 10 9 per l. Donor chimerism in whole mononuclear cells was analyzed weekly by a PCR assay of short-tandem repeat as reported previously. 16 From the clinical point of view, aGVHD was graded according to the Seattle criteria.
1 Among 9 patients who developed grades II-IV (GII-IV) aGVHD, 7 patients with gastrointestinal aGVHD (nos. 4, 12, 14, 15, 16, 32 and 33; Table 2 ) were pathologically diagnosed using biopsy specimens.
Culture of peripheral blood lymphocytes
PBMCs were separated by Ficoll-Hypaque (Histopaque-1077; Sigma Chemical Co., St Louis, MO, USA) density gradient centrifugation and then washed twice with PBS before use. A total of 1 Â 10 7 PBMCs obtained from normal volunteers were cultured and stimulated with 1 mg/ml PHA (Sigma), 100 U/ml rIL-2 (Shionogi and Co. Ltd., Osaka, Japan) and 50 ng/ml rIL-12, (Pepro Tech Inc., Rocky Hill, NJ, USA) for 5 days as reported previously. 14, 15 The whole nonadherent cells were collected for analysis of CLA expression using a FACScan flow cytometer. Activated cells increased their size and the Surface-marker analysis of CLA þ T cells after allo-SCT To determine the characteristics of CLA þ T cells in PB, we obtained lymphocytes from the normal donors (n ¼ 6) and the patients at 2-4 (n ¼ 10) and 12-14 weeks (n ¼ 7), after allo-SCT. We stained them with one of the following in addition to FITC-labeled CLA and PerCP-labeled anti-CD3 antibodies, and analyzed them by three-color flow cytometry:
Cytokine secretion by CLA þ T cells Cytoplasmic cytokine production by CLA þ T cells was assessed by cytoplasmic cytokine staining in accordance with previous reports. 17, 18 PBMCs from patients of 3-5 weeks after allo-SCT (n ¼ 5) and from normal control subjects (n ¼ 5) were stimulated with 50 ng/ml of phorbol myristate acetate (Sigma), 1 mg/ml ionomycin (Sigma), and 1 mg/ml PHA (Sigma) in an RPMI1640 medium supplemented with 50 U/ml IL-2 and GolgiPlug (Becton Dickinson) for 4 h. Activated cells were treated with Cytofix/ Cytoperm solution (PharMingen) and stained with PEconjugated isotype control antibodies, or MoAbs to IL-2, IL-4 and IFN-g (PharMingen) together with FITCconjugated HECA-452 antibody (PharMingen) and PerCP-conjugated anti-CD3 antibody (Becton Dickinson). On FACS analysis, CLA þ and CD3 þ fraction was gated and the percentages of cytokine-producing cells were measured.
Vital signs and laboratory tests
Vital signs and percutaneous oxygen saturation (SPO 2 ) were recorded three times daily after allo-SCT. Routine laboratory blood tests and biochemical analysis were performed three times weekly. Tests for the coagulation profile were performed twice weekly. We examined the correlations of these parameters with the maximum percentages of CLA þ T and NK cells from days 8 to 60.
Statistical analysis
The groups were categorized based on the grade of aGVHD and were compared using the nonparametric Dunett's tests for multiple comparisons or the MannWhitney U-test for comparison between two groups. The phenotypes of CLA þ T cells in the normal donor and patients 3 weeks or 12 weeks after allo-SCT were compared using the nonparametric Dunett's test. The probabilities of GII-IV aGVHD were determined by calculating the cumulative incidence using Kaplan-Meier curves. Hazard rates were compared using log-rank tests. The groups were stratified based on the maximum CLA þ T-cell percentage (X20% or o20%), and the hazard rates between the groups were compared using the logistic regression model because the group with o20% CLA þ T cells did not develop GII-IV aGVHD. Pearson's correlations were calculated to evaluate the association between the clinical variables and the percentages of CLA þ T or NK cells.
Results
As shown in Figure 1a , an antigen signal (PHA) and Th1-cytokine signals (IL-2 and IL-12) were both necessary for the CLA expression on T cells in vitro, whereas for that on NK cells, Th1-cytokine signals alone were sufficient. Therefore, the CLA þ T-cell fraction indicates the magnitude of the antigen signals transmitted to the T cells when the level of the signals derived from Th1 cytokines is constant. In contrast, the CLA þ NK-cell fraction indicates the level of Th1-cytokine signals. Equivalent alterations in the CLA þ T and NK-cell fractions were observed in patients after allo-SCT; around the onset of aGVHD, the CLA þ T-cell fraction in PB remarkably increased (Figure 1b) , whereas the CLA þ NK-cell fraction was not influenced significantly. These observations suggested that the T cells recognized the alloantigen in the Th1-cytokine environment in aGVHD.
The percentages of homing receptor-bearing T or NK cells after allo-SCT were plotted against time in weeks. The percentages of donor lymphocytes were plotted at week 0. The alterations in the CLA þ T cells after allo-SCT varied with each patient (data not shown); however, the average percentage was constant in the peritransplant period and comparable to that in the normal volunteers (data not shown). The aGVHD grade influenced the proportion of CLA þ T cells. After allo-SCT, the median CLA þ T-cell fraction was significantly higher in GII-IV than in grades 0-I aGVHD (Po0.0001; Figure 2a) . The difference was statistically significant in weeks 2, 3, 5 and 6 (Po0.05). Patients developing GII-IV aGVHD recorded maximum CLA þ T-cell percentages in PB either around the onset of aGVHD (2-4 weeks) or at the time of aGVHD deterioration (5-9 weeks; Figure 2a ). In patients with GII-IV aGVHD, a high CLA þ T-cell percentage, that is, X20% was first detected within 4 weeks after allo-SCT (8 of 9 CLA þ T cells and severe aGVHD J Tsuchiyama et al cases; Table 2 ), and the maximum percentage was often observed within a week of the development of GII-IV aGVHD (6 of 9 cases; Table 2 ). The maximum CLA þ Tand NK-cell percentages of each patient and the frequency of detection of X20% CLA þ T and X40% CLA þ NK cells between 2 and 12 weeks were plotted against the clinical grade of aGVHD (Figures 2b and c) . The maximum CLA þ T-cell percentage was significantly higher in GII-IV than in grades 0 and I aGVHD (Po0.01). A high percentage (X20%) of CLA þ T cells was more frequently observed in GII-IV than in grades 0 and I aGVHD (data not shown, Po0.01).
When the cutoff CLA þ T-cell percentage was set at 20%, which is approximately the same as the median CLA þ T-cell percentage in grade I GVHD (Figure 2b ) and approximately twice the median in normal volunteers, a higher level was significantly associated with the development of GII-IV aGVHD; the cumulative incidence rate of GII-IV aGVHD in the high-percentage group (CLA þ T cells X20%) was 52.9% and that in the low-percentage group (CLA þ T cells o20%) was 0% (Table 3 ; Figure 2c ; Po0.001). The sensitivity, specificity, positive predictive value, negative predictive value and odds ratio of this test for GII-IV aGVHD were 100, 66.7, 52.9, 100% and N, respectively.
In contrast, the aGVHD grade did not influence the maximum percentage or weekly alteration in the CLA þ NK-cell percentages (Figures 2a and b) . The cumulative incidence rates of GII-IV aGVHD in the high-percentage (CLA þ NK cells X40%) and low-percentage (CLA þ NK cells o40%) groups were 35.3 and 18.8%, respectively (P ¼ 0.266; Figure 2c ). The levels of L-selectin positive (LSCL þ ) T or NK cells, or clinical variables were not significantly associated with the increased risk of severe aGVHD (Table 3) .
To test the correlation of the maximum CLA þ T-and NK-cell percentages with the clinical data on days 8-60, we selected 21 aGVHD patients (n ¼ 7, grade 0; n ¼ 6, grade I; n ¼ 8, GII-IV) without other complications that would affect the clinical and laboratory findings (Table 4) . In these patients, infectious foci such as sinusitis, otitis media and skin ulcers were not documented during the pretransplantation examination. Further, sinusoidal occlusive syndrome (SOS), bacteremia with a positive blood culture, bacterial pneumonia and idiopathic pneumonia syndrome did not develop after allo-SCT. The maximum CLA þ T-cell percentage was significantly correlated with the maximum body temperature (BT; The maximum and median LSLC þ T-cell or NK cell percentages were not influenced by the grade of aGVHD (data not shown).
Cutaneous lymphocyte antigen-positive T cells collected from normal donors or from patients 3 or 12 weeks after allo-SCT expressed CD4 CD8, CD45RO, HLA-DR, CD25, LSLC and CD161 (Figure 3a) . These results indicate that the CLA þ T cells of the patients after allo-SCT belong to the memory T-cell subset like that of the donors. 10, 19 The CLA þ T cells after allo-SCT expressed high levels of CCR4 and CCR6, which is comparable to those in the normal donors. 17 Cutaneous lymphocyte antigen-positive T cells after allo-SCT produced comparable levels of IFN-g and IL-2 to that of normal donors even though immunosuppressive drugs were administered after allo-SCT (Figure 3b ). Therefore, CLA þ T cells that emerge after allo-SCT are likely to have been produced in a Th1 environment and comprise a major source of IL-2 and IFN-g in the post transplant period.
Discussion
In this study, we showed that CLA þ T-cells were an immunological marker for aGVHD in clinical settings; CLA þ T cells often increased 3-7 days before the onset of aGVHD and CLA þ T-cell percentage in PB correlated with the clinical grade of aGVHD. These results are consistent with findings by Beilhack et al., 20 who noted that T cells expressing skin homing receptors increased in peripheral lymph nodes and spleen 3 days before the migration to the skin and onset of aGVHD in murine system. We also showed that the alterations in CLA þ NK cells were not different in aGVHD and non-aGVHD, which suggests that the skewing to the Th1-cytokine environment appears to be a common phenomenon occurring within 4 weeks post transplant as mentioned above. The difference between the kinetics of CLA þ T and NK cells indicates that the magnitude of the antigen signal, not the cytokine-mediated signals, determines the aGVHD severity in allo-SCT with one-locus mismatch or HLAmatched allo-SCT. This finding is consistent with previous studies that suggest a correlation of aGVHD severity and prognosis with the HLA disparity in human HLAmismatched transplantation, as HLA-mismatch provides a strong input-signal to the donor T-cells through CD3 molecules. The CLA þ T cells that emerge in patients after allo-SCT exhibit almost identical characters as those of normal volunteers, 10, 17 most of these belong to the memory T-cell subset, 19 express activation markers and produce high levels of Th1 cytokines after short-term stimulation. This cytokine-production pattern of CLA þ T cells is compatible with the finding that IL-2 and IL-12 are essential for the in vitro induction of CLA expression on T and NK cells as IL-12 plays a central role in the Th1 differentiation of T cells. 22, 23 As the CLA þ T cells produce high levels of TNF-a (data not shown) as well as IL-2 and IFN-g, they function not only as a marker of aGVHD but are also candidates for the direct effector cells that induce organ damage in aGVHD.
We showed that the maximum CLA þ T-cell percentage correlated significantly with a high BT and FDP D-dimer level and low SPO 2 that indicate severe acute inflammation, organ damage and increased vascular permeability, respectively. Th1 cytokines produced by CLA þ T cells appear to be partly responsible for these physiological and biochemical derangements in aGVHD. [24] [25] [26] In clinical practice, to detect aGVHD early after allo-SCT, we usually pay attention to the cutaneous, intestinal or hepatic symptoms. Our results emphasize the importance of acute inflammation as an early manifestation of aGVHD. The continuous monitoring of these three parameters may be useful for the supplementary diagnosis and assessment of aGVHD severity when the proportion of the CLA þ T cells cannot be measured by flowcytometry.
Lymphocyte homing receptors recruit the lymphocytes to the specific organs; CLA and a4b7 integrin mediate the constitutive trafficking of lymphocytes to the skin and the intestine, respectively. It seems reasonable that these homing receptors recruit the effector cells to the skin and intestine in aGVHD, respectively. The involvement of a4b7 integrin in intestinal aGVHD has been previously demonstrated. 27 Beihack et al. 20 showed that before the onset of aGVHD, T cells in mesenteric lymph nodes and Peyer's patches upregulated the a4b7 integrin. Moreover, the association between CLA and cutaneous aGVHD has been suggested in human system; CLA þ T cells infiltrated into cutaneous aGVHD lesion. 15 Beihack et al. 20 also showed that before the onset of aGVHD, T cells in peripheral lymph nodes and spleen upregulate the skin homing receptor in murine aGVHD. Further, it seems likely that T cells expressing skin-homing receptors are able to migrate to target organs other than skin. Stacey et al. 28 showed that the pretreatment of donor lymphocytes with neuraminidase decreases the incidence of aGVHD in murine models. This study is indirect evidence suggesting the involvement of the murine counterpart of CLA in the systemic aGVHD reaction as CLA is a sialylated 12, 14 It was also shown that Th1 T cells expressing skin homing receptors can migrate to the intestinal laminapropria, and are associated with inflammation in the intestine. 29 Further, the CLA þ T cells that emerge after allo-SCT express high levels of CCR4 and CCR6, which is comparable to that of the normal donors.
17 CCL20 (macrophage inflammatory protein 3a), the CCR6 ligand, is expressed by various mucosal epithelial cells such as those of the respiratory tract, gastrointestinal tract, liver, genitourinary tract and the skin, [30] [31] [32] whereas the CCR4 ligands, CCL17 (thymus and activation-regulated chemokine) and CCL22 (macrophage-derived chemokine) are expressed by cutaneous dendritic cells, 33 keratinocytes, 34 bronchial epithelial cells, [35] [36] [37] nasal mucosal epithelium, 38 endometrial epithelium 39 and corneal fibroblasts. 40 CLA þ T cells seem to have ability to migrate to various target organs of aGVHD with the assistance of CCR4 or CCR6. Our clinical data and the characteristic expression of chemokine receptors on CLA þ T cells strongly suggest that CLA þ T cells may be involved in systemic as well as cutaneous aGVHD.
Recently, using tetrameric HLA-class I-minor histocompatibility antigen-peptide complexes, it has been demonstrated that some minor mHAs are involved in the acute graft-versus-host reaction in the HLA-matched allo-SCT patients. 41, 42 As demonstrated in a series of basic experiments, antigen stimulation is necessary for the expansion of the CLA þ T-cell population. Therefore, a substantial number of alloantigen-reactive T cells must be included in the CLA þ T-cell fraction after HLA-matched allo-SCT. The percentage of T cells bearing a specific TCR against a well-known mHA was reported to be 3-10% of CD8 þ T cells after allo-SCT. This percentage was smaller than the whole CLA þ T-cell population after allo-SCT, and specific repertoires against unknown mHA may be included in this population. Novel mHAs may be detected by analyzing the TCR repertoire expressed by the CLA þ T-cell population. 
